



Celator Pharmaceuticals Inc. (NASDAQ: CPXX) to Ring The NASDAQ Stock Market Closing Bell

ADVISORY, Sept. 16, 2014 (GLOBE NEWSWIRE) --

What:

Celator Pharmaceuticals Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, will visit the NASDAQ MarketSite in Times Square.

The Celator team, led by **CEO, Mr. Scott Jackson**, will ring the Closing Bell to celebrate the Company's achievements since it started trading on The NASDAQ Stock Market last November.

Where:

NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio

When:

Wednesday, September 17, 2014 - 3:45 p.m. to 4:00 p.m. ET

Contact:

Beth DelGiacco
(212) 362-1200
Beth@sternir.com

NASDAQ MarketSite:

Christine Barna
(646) 441-5310
Christine.Barna@nasdaqomx.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: <http://www.facebook.com/NASDAQ>.

For photos from ceremonies and events visit our Instagram Page: <http://instagram.com/nasdaq>.

For news tweets, please visit our Twitter page at: <http://twitter.com/nasdaqomx>.

For exciting viral content and ceremony photos visit Tumblr Page: <http://nasdaq.tumblr.com/>.

Webcast:

A webcast of the NASDAQ Closing Bell will be available at: <https://new.livestream.com/nasdaq/live> or <http://www.nasdaq.com/about/marketsitetowervideo.aspx>.

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Celator Pharmaceuticals Inc. (Nasdaq:CPXX):

Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes lead product, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage product candidate; CPX-8 (a hydrophobic docetaxel prodrug nanoparticle formulation) being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory; and a program exploring novel combinations of existing drugs, including targeted therapies.

For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.

About NASDAQ OMX Group

NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over \$8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.

-NDAQA-



Source: The NASDAQ OMX Group, Inc.

News Provided by Acquire Media